Clinical Trial

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-16
notable Enrollment reduced: 25 -> 15 participants 2026-05-16
notable Primary completion pushed: 2026-07 -> 2026-11 2026-05-16
minor Completion pushed: 2027-01 -> 2027-02 2026-05-16
Trial Details
NCT Number NCT07116746
Lead Sponsor Arthrosi Therapeutics
Conditions Gout, Gouty Arthritis, Hyperuricemia, Gout Chronic, Refractory Gout, Uncontrolled Gout, Tophaceous Gout
Enrollment 15 participants
Start Date 2025-12-03
Primary Completion 2026-11 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-15